Sort
82,697 grants matching “vaccine development”
Allergen T cell epitopes and phenotypes in peanut allergy and immunotherapy
$818,508William W. Kwok · Benaroya Research Inst At Virginia Mason · U19 · FY2021 · AI
EVASION OF HOST IMMUNE RESPONSE BY INFLUENZA VIRUS
$818,463Mount Sinai School Of Medicine Of Nyu · P01 · FY2003 · AI
CoVPN 5001 - A prospective study of acute immune responses to SARS-CoV-2 infection
$818,451Peter B. Gilbert · Fred Hutchinson Cancer Research Center · UM1 · FY2022 · AI
NIAID Preclinical Development Support: Essential Core Activities
$818,424Timothy Fouts · Advanced Bioscience Laboratories, Inc. · N01 · FY2022 · AI
Inhibitors and Probes of HIV-1 Cell Fusion
$818,419Carole Bewley · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2015 · DK
NK cell-mediated regulation of T cell immunity in TB/HIV co-infection
$818,412Cheryl Liane Day · Emory University · R01 · FY2017 · AI
UPR/MDACC: Partnership for Excellence in Cancer Research (1 of 2)
$818,406Elizabeth L Travis · University Of Tx Md Anderson Can Ctr · U54 · FY2019 · CA
Trypanosome Transmission Biology in Tsetse
$818,379Serap Aksoy · Yale University · R01 · FY2025 · AI
A vaccine for genital herpes that achieves sterilizing immunity
$818,356Harvey Michael Friedman · University Of Pennsylvania · R01 · FY2019 · AI
PEDIATRIC AIDS CLINICAL TRIAL UNIT
$818,332Univ Of Massachusetts Med Sch Worcester · U01 · FY2001 · AI
Developmental and Mentoring Core
$818,278Ingrid Valerie Bassett · Harvard University · P30 · FY2020 · AI
Defining the impact of interpersonal gut microbiota variation on oral cholera vaccine responsiveness
$818,255Ansel Hsiao · University Of California Riverside · R01 · FY2024 · AI
Cervical, Anal, and Oral HPV Persistence and Risk Factors Among Adolescent Girls
$818,235Angela Diaz · Icahn School Of Medicine At Mount Sinai · R01 · FY2008 · AI
Host control in Coccidioidomycosis
$818,219John N Galgiani · University Of Arizona · P01 · FY2007 · AI
Project 2: Serologic and molecular determinants of COVID-19 severity and immune protection
$818,164Linda J. Saif · Ohio State University · U54 · FY2020 · CA
HLA Chip Product for FDA 510K Approval
$818,088Krishna Jayaraman · Genomics Usa, Inc. · R44 · FY2009 · AI
Temporal Phenotypes and Risk Models for the Post-COVID Syndrome and its sub-types
$818,071Hossein Estiri · Massachusetts General Hospital · R01 · FY2024 · AI
Temporal Phenotypes and Risk Models for the Post-COVID Syndrome and its sub-types
$818,071Hossein Estiri · Massachusetts General Hospital · R01 · FY2023 · AI
Rational development of a vaccine against tick-borne rickettsioses
$818,015Rong Megan Fang · University Of Texas Med Br Galveston · R01 · FY2022 · AI
Host control in Coccidioidomycosis
$817,883John N Galgiani · University Of Arizona · P01 · FY2006 · AI
Impairment of anti-Plasmodium T cell memory by type I Interferon Signaling
$817,729Nana Kwaku Minkah · Seattle Children'S Hospital · R01 · FY2023 · AI
Mechanisms of Protection of Universal Therapeutic Antibodies to Influenza A
$817,703Silke Paust · Scripps Research Institute, The · R01 · FY2020 · AI
Host Genetic Determinants of HIV Pathogenesis
$817,656Sunil K Ahuja · University Of Texas Hlth Science Center · R37 · FY2008 · AI
Immunologic and Metabolic Profiles of T cells that control diverse HCV infections
$817,644Andrea L Cox · Johns Hopkins University · U19 · FY2021 · AI
Development of an effective therapy against post-exposure Anthrax
$817,642Maurizio Pellecchia · Sanford Burnham Prebys Medical Discovery Institute · U01 · FY2010 · AI